Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin versus placebo for cardiovascular biomarker expression after STEMI in type 2 diabetes
IRCT20241106063619N1Phase 4Completed
- Sponsor
- Zanjan University of Medical Sciences
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, triple-blind trial in type 2 diabetes mellitus (T2DM) and myocardial infarction (MI) comparing Empagliflozin with Placebo (2 arms). Primary endpoints: Cardiotrophin-1 transcript expression and GDF-15 transcript expression. Started Sep 2024; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)myocardial infarction (MI)
Beyond the preview
Go deeper on IRCT20241106063619N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20241106063619N1.